Oncternal Therapeutics (NASDAQ:ONCT) Receives New Coverage from Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a note issued to investors on Monday. The firm set a “hold” rating on the stock.

Separately, HC Wainwright cut their price objective on Oncternal Therapeutics from $28.00 to $19.00 and set a “buy” rating for the company in a report on Monday, May 13th.

Oncternal Therapeutics Trading Up 1.2 %

Shares of ONCT opened at $9.21 on Monday. Oncternal Therapeutics has a 12 month low of $5.57 and a 12 month high of $13.14. The firm has a fifty day simple moving average of $8.65 and a 200 day simple moving average of $8.58. The stock has a market capitalization of $27.26 million, a price-to-earnings ratio of -0.75 and a beta of 1.28.

Oncternal Therapeutics (NASDAQ:ONCT) last released its earnings results on Thursday, May 9th. The company reported ($2.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.88) by $0.05. Oncternal Therapeutics had a negative return on equity of 107.67% and a negative net margin of 3,160.73%. The business had revenue of $0.57 million for the quarter, compared to analyst estimates of $0.18 million. During the same quarter in the prior year, the company posted ($4.00) earnings per share. As a group, research analysts predict that Oncternal Therapeutics will post -10.12 earnings per share for the current fiscal year.

Insider Buying and Selling at Oncternal Therapeutics

In other Oncternal Therapeutics news, Director Robert James Wills bought 6,914 shares of Oncternal Therapeutics stock in a transaction dated Thursday, March 28th. The stock was bought at an average cost of $8.48 per share, for a total transaction of $58,630.72. Following the purchase, the director now owns 6,914 shares of the company’s stock, valued at approximately $58,630.72. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 11.20% of the company’s stock.

Institutional Trading of Oncternal Therapeutics

An institutional investor recently bought a new position in Oncternal Therapeutics stock. Quantum Private Wealth LLC acquired a new position in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 27,806 shares of the company’s stock, valued at approximately $250,000. Quantum Private Wealth LLC owned approximately 0.94% of Oncternal Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 16.05% of the company’s stock.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.